The company markets and distributes high-end specialty pharmaceutical products in India, primarily focusing on oncology, cardiovascular, renal, and rare diseases, sourced from its global parent group.
The company possesses a narrow moat derived from exclusive access to the parent group's patented global pipeline and high switching costs in specialty therapies like oncology. While revenue growth is high, the average net margin of 6.5% and ROCE of 18.4% suggest that significant value is captured by the parent through transfer pricing, limiting the local entity's pricing power.
Management has transitioned to a capital-light model by exiting local manufacturing to focus on high-margin specialty distribution. Earnings are primarily used to fund working capital for new launches and pay consistent dividends, though substantial cash is retained on the balance sheet.
The investment collapsed as the parent entity prioritized global profits over the Indian subsidiary's minority shareholders through aggressive transfer pricing, keeping local net margins suppressed despite high revenue growth. The exit from local manufacturing left the company as a mere distribution arm, vulnerable to the NPPA's aggressive price controls which eventually wiped out the thin 6.5% margins. A leadership vacuum caused by frequent MD turnovers led to poor execution during a period of intense generic competition for key oncology patents, while the cash-heavy balance sheet was eroded by legal settlements and inefficient working capital management.
RichFakir rates Astrazeneca Pharma India Ltd's business quality as decent — 65/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Astrazeneca Pharma India Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Astrazeneca Pharma India Ltd is: Watch — wait for price. A decent business, but at an expensive price against our estimate of fair value — one to keep on the watchlist for a better entry.
RichFakir's educational estimate of Astrazeneca Pharma India Ltd's fair value is about ₹1,329 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →